Abstract Background: The renin-angiotensin system(RAS) has a major role in development of diabetic nephropathy and blocking of RAS by inhibitors and blocking of angiotesin receptors is standard treatment for preventing kidney disease and proteinuria. It is reported that VIT-D analogues are able to suppress renin exertion and improve proteinuria. The aim of this study is to evaluate the effect of VitD analogue (calitriol) on reducing proteinuria in patients with diabetic nephropathy. Materials and Methods: In this clinical trial study, 132 eligible patients that had diabetic nephropathy and hadn’t vit D deficiency were selected. The patients were divided into two equal groups. First group received the combination of losartan 25mg twice dai...
Background: Prior studies suggest that vitamin D therapy may decrease cardiovascular disease risk in...
Vitamin D receptor agonists (VDRAs) inhibit the renin–angiotensin system (RAS) and reduce podocyte l...
Background Despite treatment with renin angiotensin aldosterone system (RAAS) inhibitors, patients w...
Objective: This study was designed to determine the synergistic effect of vitamin D analog added to ...
Residual proteinuria, the amount of proteinuria that remains during optimally dosed renin-angiotensi...
Despite renin-angiotensin-aldosterone system blockade, which retards progression of CKD by reducing ...
Residual proteinuria, the amount of proteinuria that remains during optimally dosed renin-angiotensi...
Despite renin-angiotensin-aldosterone system blockade, which retards progression of CKD by reducing ...
Background: Urinary angiotensinogen (UAGT) is supposed to be a marker of activation of the intrarena...
Optimal albuminuria reduction is considered essential to halting chronic kidney disease (CKD) progre...
Background: Patients with diabetic nephropathy are at high risk for further progressive renal functi...
Background: Patients with diabetic nephropathy are at high risk for further progressive renal functi...
Optimal albuminuria reduction is considered essential to halting chronic kidney disease (CKD) progre...
ANTIPROTEINURIC TREATMENT REDUCES URINARY EXCRETION OF VITAMIN D-BINDING PROTEIN IN PATIENTS WITH CH...
Background Despite treatment with renin angiotensin aldosterone system (RAAS) inhibitors, patients w...
Background: Prior studies suggest that vitamin D therapy may decrease cardiovascular disease risk in...
Vitamin D receptor agonists (VDRAs) inhibit the renin–angiotensin system (RAS) and reduce podocyte l...
Background Despite treatment with renin angiotensin aldosterone system (RAAS) inhibitors, patients w...
Objective: This study was designed to determine the synergistic effect of vitamin D analog added to ...
Residual proteinuria, the amount of proteinuria that remains during optimally dosed renin-angiotensi...
Despite renin-angiotensin-aldosterone system blockade, which retards progression of CKD by reducing ...
Residual proteinuria, the amount of proteinuria that remains during optimally dosed renin-angiotensi...
Despite renin-angiotensin-aldosterone system blockade, which retards progression of CKD by reducing ...
Background: Urinary angiotensinogen (UAGT) is supposed to be a marker of activation of the intrarena...
Optimal albuminuria reduction is considered essential to halting chronic kidney disease (CKD) progre...
Background: Patients with diabetic nephropathy are at high risk for further progressive renal functi...
Background: Patients with diabetic nephropathy are at high risk for further progressive renal functi...
Optimal albuminuria reduction is considered essential to halting chronic kidney disease (CKD) progre...
ANTIPROTEINURIC TREATMENT REDUCES URINARY EXCRETION OF VITAMIN D-BINDING PROTEIN IN PATIENTS WITH CH...
Background Despite treatment with renin angiotensin aldosterone system (RAAS) inhibitors, patients w...
Background: Prior studies suggest that vitamin D therapy may decrease cardiovascular disease risk in...
Vitamin D receptor agonists (VDRAs) inhibit the renin–angiotensin system (RAS) and reduce podocyte l...
Background Despite treatment with renin angiotensin aldosterone system (RAAS) inhibitors, patients w...